Artelon® Tissue Reinforcement receives regulatory clearance for the marketing of new indications in the USA

Artelon® Tissue Reinforcement receives regulatory clearance for the marketing of
new indications in the USA

Västra Frölunda, Sweden, September 21, 2007
The biomaterials company Artimplant has received regulatory clearance for
marketing Artelon® Tissue Reinforcement for new indications in the USA. The new
clearance offers the opportunity to reach a considerably larger market.

Since 2006 it has been possible to market Artelon® Tissue Reinforcement in the
USA as reinforcement of soft tissue tears in the shoulder, limited to the
supraspinatus tendon. The present regulatory clearance provides Artimplant and
its licensee, Biomet Sports Medicine, with the opportunity to market the product
for general soft tissue repair. Examples of new indications that can be marketed
are general reinforcement of the rotator cuff in the shoulder and tendon repair
around the kneecap, biceps, front thigh muscle (quadriceps) and Achilles tendon.


In addition to using sutures or suture anchors for primary repair, patients with
severe injury or poor tissue quality will benefit from additional support
provided by the Artelon® reinforcement patch. The patch offers additional
initial mechanical strength and is at the same time a degradable scaffold for
in-growth of the patient's native tissue. The long-term support from the
degradable patch should minimize the risk of re-ruptures and the aim is to
accelerate rehabilitation and increase long-term strength. With the Artelon®
reinforcement patch the risk of tissue reaction or disease transfer related to
animal- or human-derived materials is eliminated. Biomet Sports Medicine's
current marketing of the product is limited to the rotator cuff of the shoulder
under the brand name SportMesh™. 

President and CEO Hans Rosén says; “The new regulatory clearance is of great
importance for Artimplant. We now have the opportunity to market Artelon® Tissue
Reinforcement on a considerably larger market than before. Artimplant's
experience from Europe in, among other things, the treatment of Achilles tendon
ruptures, which can now be marketed in the USA, is very encouraging. Artelon®
Tissue Reinforcement has a broad field of use, significant market potential and
the scope to becoming substantially bigger than our current best-selling product
Artelon® CMC Spacer. The clearance can be regarded as an important step for
Artimplant.”

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.